PhD positions in Co-Fund project on Personalized medicine in chronic diseases with a focus on diabetes

Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). In addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
Rhapsody is funded under the "Health" priority, which is an investment in our health and, on a larger scale, an investment in a healthy workforce, a healthy economy and lower public health bills.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

EFPIA brings together 33 European national pharmaceutical industry associations as well as 42 leading companies undertaking research, development and the manufacture in Europe of medicinal products for human use.
The EFPIA Manager Research Partnerships plays a critical role in enabling participation of EFPIA members in collaborative research and development in the framework of private-private and public-private partnerships, such as but not limited to the Innovative Medicines Initiative or EU framework programmes.

The State Secretariat for Education, Research and Innovation SERI within the Federal Department of Economic Affairs, Education and Research EAER is the Swiss federal government's specialised agency for national and international matters concerning education, research and innovation policy.